Bendamustine plus rituximab for treatment of WM: patient outcomes and impact of dosing

Key Findings

• ●250 WM patients treated with BR in frontline and relapsed settings
• ●Frontline response rate (PR or better) 91.4% vs 73.9% in relapsed
• ●Major multicenter study establishing BR efficacy in WM

Referenced in (1 disease)